Non-invasive cancer monitiring: liquid biopsy at your hands
Big Idea
RUBYnanomed was founded in 2018 as a spin-off of INL and aims to bring lab discoveries to the clinical market. RUBYnanomed has developed the RUBYchipTM: a microfluidic-based, liquid biopsy device for isolating all types of CTCs, while enabling the analysis of their phenotypic, genetic and functional characteristics, facilitating unprecedently frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. RUBYchipTM enables oncologists to detect and analyse the evolution of cancer subtype and therapeutic resistance mechanisms in each patient, providing personalised therapy insights to treat their patients.
Activity Highlights
- Exame de Informática Award 2022
- European Innovation Council Women Innovators Prize, 2021
- Elevator Pitch Competition (EPiC), First prize – health technologies. Organised by Hong Kong Science and Technology Parks Corporation (HKSTP), Hong Kong, 2020
- Industry Award, INL, PT, 2020
- IPA4SME, European Commission for Seal of Excellence projects in EIC funding call, PT/EU, 2020
- Winner of the Royal Society of Chemistry Emerging Technologies Competition in the category of Health, London, UK – first prize, UK, 2019
- AdMaCom (Berlin, Germany) – first prize, DE, 2018
- Everis, RUBYnanomed, semifinalists (20 best among 1000 applications), ES, 2018
- RESOLVE – for scale-up and pre-clinical trials for breast cancer, PT, 2017
- Startup Braga – Prize: Boston Roadshow for the company of 1 week, PT, 2017
- StartupNano – first prize, in-kind services and facilities for incubation, PT, 2017
Team
Lorena Diéguez – CEO; Sara Abalde-Cela – CTO; Paulina Piairo – COO.
Portugal Ventures’ Investment Manager
